Predictive factors for omitting lymphadenectomy in patients with node‐positive breast cancer treated with neo‐adjuvant systemic therapy-Reference-Cited by-同舟云学术

Predictive factors for omitting lymphadenectomy in patients with node‐positive breast cancer treated with neo‐adjuvant systemic therapy

Published:2020-02-13 Issue:5 Volume:26 Page:888-896
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Fernandez‐Gonzalez Sergi¹^ORCID,Falo Catalina²,Pla Maria J.¹,Verdaguer Paula¹,Nuñez Diana¹,Guma Anna³,Soler Teresa⁴,Vethencourt Andrea²,Vázquez Silvia¹,Fernandez‐Montoli Maria Eulalia¹,Campos Miriam¹,Pernas Sonia²,Gil Miguel²,Ponce Jordi¹,Garcia‐Tejedor Amparo¹

Affiliation:

1. Multidisciplinary Breast Cancer Unit Department of Gynecology Hospital Universitari Bellvitge Idibell Barcelona Spain

2. Multidisciplinary Breast Cancer Unit Department of Oncology Institut Català d'Oncología Barcelona Spain

3. Multidisciplinary Breast Cancer Unit Department of Radiology Hospital Universitari Bellvitge Idibell Barcelona Spain

4. Multidisciplinary Breast Cancer Unit Department of Pathology Hospital Universitari Bellvitge Idibell Barcelona Spain

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.13763

Reference36 articles.

1. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

2. Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy

3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

4. Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant Chemotherapy

5. HHS public access;Mittendorf EA;Nat Prod Rep,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?;The Breast;2024-02

2. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment;European Journal of Surgical Oncology;2023-10

3. Neoadjuvant Therapy and Axillary Lymph Node Status in HER2-Positive Breast Cancer;Cancer Investigation;2023-07-03

4. ¿La quimioterapia neoadyuvante proporciona algún beneficio para la desescalada quirúrgica en el cáncer de mama HER2 (Ó?) luminal B?;Cirugía y Cirujanos;2023-04-21

5. Targeted Axillary Dissection with 125I Seed Placement Before Neoadjuvant Chemotherapy in a Danish Multicenter Cohort;Annals of Surgical Oncology;2023-04-16